Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
manilatimes14h
Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...
pharmaphorum14h
Pliant slumps on decision to pause lung disease drug trial
Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 trial of its lead drug for idiopathic pulmonary fibrosis (IPF) after seeing a ...
Peninsula biotech sheds 60% of its value as it pauses key clinical trial
A Peninsula biotech company focusing on a deadly lung-scarring disease lost more than half its stock value Monday after ...
Health Digest on MSN13h
The 10 Leading Causes Of Death In America
In the United States, the annual death rate is at over three million. Knowing the top ten diseases responsible for U.S.
The Lancet4h
Management and mechanisms of eosinophil action in asthma: mind the gap?
The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...
Healio15h
Odds for injurious fall heightened with fall-risk increasing drug prescription in COPD
The adjusted likelihood for an injurious fall in adults with COPD was elevated with a fall-risk increasing drug prescription, ...